Representativeness of Histologies in Clinical Practice

EP: 1.Introducing KEYNOTE-B61 in Non–Clear Cell RCC

EP: 2.Challenges in Treating Non–Clear Cell RCC

EP: 3.Study Design and Patient Population

Now Viewing

EP: 4.Representativeness of Histologies in Clinical Practice

Representativeness of Histologies in Clinical Practice

The histologic distribution in the KEYNOTE-B61 study accurately reflects the real-world clinical experience with patients with non–clear cell RCC seen in major cancer centers. The study population's composition mirrors what clinicians encounter in routine practice, with papillary RCC representing the most common subtype among non–clear cell variants, followed by chromophobe RCC as the second most frequent. This distribution pattern aligns precisely with the clinical experience at major academic medical centers, validating the study's relevance to everyday clinical decision-making.

The study's inclusion of unclassified and translocation RCC rounds out the representation of the 4 most commonly encountered non–clear cell RCC subtypes in clinical practice. These 4 histologic variants comprise the vast majority of non–clear cell RCC cases that oncologists treat, making the study population highly representative of the patient population that clinicians face. Rare variants such as succinate dehydrogenase-deficient RCC and other specialized subtypes represent only 2% to 3% of the non–clear cell population and are infrequently encountered in routine practice.

The substantial sample size of approximately 150 patients in the KEYNOTE-B61 study provides sufficient statistical power to capture the full spectrum of non–clear cell RCC variants and their treatment responses. This large cohort size is particularly valuable given the rarity of individual non–clear cell subtypes, allowing for meaningful analysis across different histologies. The study's comprehensive representation of non–clear cell RCC subtypes enhances confidence in applying the results to diverse patient populations encountered in clinical practice, making it a valuable reference for treatment decisions across the spectrum of non–clear cell RCC.